Charles River Laboratories International, Inc.
https://www.criver.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Charles River Laboratories International, Inc.
Finance Watch: Arbor, Acrivon, Bit.Bio Close VC Mega-Rounds
Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.
Cell And Gene Therapy Manufacturing: Catalent Snaps Up MaSTherCell
Consolidation and acquisitions among contract manufacturers of cell and gene therapies is a growing trend, as Catalent acquires Belgium- and US-based MaSTherCell Global for $315m, and other cell and gene therapy manufacturers address capacity shortages.
Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.
Time For AI To Deliver In Drug Discovery, Says Atomwise CEO
Having signed a multi-year, multi-target agreement with Lilly worth potentially $550m, Atomwise CEO Abe Heifets tells Scrip the burden of proof is on AI practitioners to start producing relevant and actionable data.
Company Information
- Industry
- Contract Research Organization-CRO
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
-
Laboratory Testing Services
- Anatomical Pathology
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Accugenix Inc.